Abstract

To investigate the effect of Jiangzhi tablet on serum indexes of mice with fatty liver induced by CCL4, 60 mice were randomly divided into blank control group, model group, positive group, high, middle and low dose group. High fat diet fed mice for 2 weeks, in second the beginning of the weekend, each group of experimental animal except the blank group in the afternoon 1:00 subcutaneous injection of 40% CCl4 of edible oil (0.05 mL/10g, 2 times / week) for modeling; at the same time, 9:00 in the morning to lipid-lowering tablets LARGEMEDTUM and small dose group (0.1125g/ml, 0.05625g/ml, 0.02815g/ml) and Gantai tablet group (0.045g/ml) mice fed with corresponding drugs, the model group received the same volume of physiological saline. At the end of the fifth week, the eyeballs were collected and the serum was separated. The levels of serum triglyceride, high density lipoprotein, low density lipoprotein, serum AST, ALT and ALP were detected. Compared with the model group, Dongbao Gantai group, Jiangzhi tablets, high dose group had significantly decreased TG and LDL content in serum of mice (p<0.01), significantly increased the content of HDL (p<0.01); Jiangzhi tablets low dose group can significantly reduce TG and LDL content in serum (p<0.05), high HDL content increased significantly in the serum of mice (p<0.01). Dongbao Gantai group, Jiangzhi tablet high dose group and middle dose group could significantly reduce the content of ALT, ALP, AST in serum of mice (p<0.01), lipid-lowering tablets in small dose group can significantly reduce ALP and AST content in serum (p<0.01), decreased the content of ALT in serum of mice (p<0.05). The high, middle and low dose groups of Jiangzhi tablets have a better intervention effect on the mice model of fatty liver induced by small dose of carbon tetrachloride.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.